Semaglutide and tirzepatide medications have transformed weight loss, diabetes management, and overall health in recent years. Now, people in China will have access to Wegovy, potentially at a much lower price than in the United States.
According to Reuters and CNN, Novo Nordisk announced Monday that it has launched its popular obesity drug Wegovy in China, the world’s second-largest pharmaceuticals market, where more than 180 million people live with obesity.
